CN1429222A
(zh)
*
|
2000-02-17 |
2003-07-09 |
安姆根有限公司 |
激酶抑制剂
|
ES2324981T3
(es)
*
|
2000-12-21 |
2009-08-21 |
Smithkline Beecham Corporation |
Pirimidinaminas como moduladores de la angiogenesis.
|
US7153871B2
(en)
|
2001-01-22 |
2006-12-26 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
|
US7205320B2
(en)
|
2001-01-22 |
2007-04-17 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
US20030139435A1
(en)
|
2001-06-26 |
2003-07-24 |
Gulzar Ahmed |
N-heterocyclic inhibitors of TNF-alpha expression
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
PT1438053E
(pt)
*
|
2001-10-17 |
2008-09-25 |
Boehringer Ingelheim Int |
Derivados de pirimidina, medicamento contendo estes compostos, sua utilização e processo para a sua preparação
|
ES2303565T3
(es)
*
|
2001-11-01 |
2008-08-16 |
Janssen Pharmaceutica Nv |
Derivados de aminobenzamida como inhibidores de la glucogeno sintasa cinasa 3beta.
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
ES2290479T3
(es)
|
2002-03-01 |
2008-02-16 |
Smithkline Beecham Corporation |
Diamino-pirimidinas y su uso como inhibidores de la angiogenesis.
|
AU2003276125B2
(en)
*
|
2002-06-17 |
2007-05-17 |
Smithkline Beecham Corporation |
Chemical process
|
WO2004009552A1
(en)
|
2002-07-19 |
2004-01-29 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
|
CN101423497A
(zh)
*
|
2002-07-19 |
2009-05-06 |
记忆药物公司 |
作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物
|
MXPA05001096A
(es)
|
2002-07-29 |
2005-11-23 |
Rigel Pharmaceuticals Inc |
Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
|
WO2004032882A2
(en)
*
|
2002-10-10 |
2004-04-22 |
Smithkline Beecham Corporation |
Chemical compounds
|
US7087625B2
(en)
|
2002-11-19 |
2006-08-08 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
UA80767C2
(en)
*
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
WO2004056807A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
US20040167132A1
(en)
*
|
2003-01-16 |
2004-08-26 |
Geetha Shankar |
Methods of treating conditions associted with an Edg-2 receptor
|
ES2325440T3
(es)
|
2003-02-20 |
2009-09-04 |
Smithkline Beecham Corporation |
Compuestos de pirimidina.
|
RS53476B
(en)
|
2003-07-18 |
2014-12-31 |
Amgen Fremont Inc. |
Hepatocyte Growth Factor Binders
|
KR20120062863A
(ko)
|
2003-07-30 |
2012-06-14 |
리겔 파마슈티칼스, 인크. |
자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물
|
DE602004032446D1
(de)
|
2003-08-07 |
2011-06-09 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
|
ZA200603719B
(en)
*
|
2003-11-06 |
2007-09-26 |
Celgene Corp |
Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders
|
WO2005105094A2
(en)
*
|
2004-04-16 |
2005-11-10 |
Smithkline Beecham Corporation |
Cancer treatment method
|
EP1751142A1
(en)
|
2004-05-14 |
2007-02-14 |
Pfizer Products Incorporated |
Pyrimidines derivatives for the treatment of abnormal cell growth
|
MXPA06013165A
(es)
|
2004-05-14 |
2007-02-13 |
Pfizer Prod Inc |
Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
|
JP2007537235A
(ja)
|
2004-05-14 |
2007-12-20 |
ファイザー・プロダクツ・インク |
異常細胞増殖の治療用ピリミジン誘導体
|
JP4812763B2
(ja)
|
2004-05-18 |
2011-11-09 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
|
WO2006020564A1
(en)
*
|
2004-08-09 |
2006-02-23 |
Smithkline Beecham Corporation |
Pyrimidin derivatives for the treatment of multiple myeloma
|
EP1799652A1
(en)
*
|
2004-10-13 |
2007-06-27 |
Wyeth |
N-benzenesulfonyl substituted anilino-pyrimidine analogs
|
GB2420559B
(en)
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
CN100516049C
(zh)
|
2004-11-16 |
2009-07-22 |
永信药品工业股份有限公司 |
抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成
|
CA2584295C
(en)
|
2004-11-24 |
2014-08-26 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
MX2007006230A
(es)
|
2004-11-30 |
2007-07-25 |
Amgen Inc |
Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
|
EP2161275A1
(en)
|
2005-01-19 |
2010-03-10 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
US8227455B2
(en)
|
2005-04-18 |
2012-07-24 |
Rigel Pharmaceuticals, Inc. |
Methods of treating cell proliferative disorders
|
WO2006129100A1
(en)
*
|
2005-06-03 |
2006-12-07 |
Glaxo Group Limited |
Novel compounds
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2007042504A2
(fr)
|
2005-10-07 |
2007-04-19 |
Guerbet |
Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
|
US8986650B2
(en)
|
2005-10-07 |
2015-03-24 |
Guerbet |
Complex folate-NOTA-Ga68
|
ES2359517T3
(es)
|
2005-11-29 |
2011-05-24 |
Glaxosmithkline Llc |
Procedimiento de tratamiento del cáncer.
|
CA2631173A1
(en)
*
|
2005-11-29 |
2007-06-07 |
Smithkline Beecham Corporation |
Treatment method
|
US20080108664A1
(en)
|
2005-12-23 |
2008-05-08 |
Liu Belle B |
Solid-state form of AMG 706 and pharmaceutical compositions thereof
|
TW200736232A
(en)
*
|
2006-01-26 |
2007-10-01 |
Astrazeneca Ab |
Pyrimidine derivatives
|
AR059066A1
(es)
*
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
ES2353482T3
(es)
|
2006-02-10 |
2011-03-02 |
Amgen, Inc |
Formas hidrato de amg706.
|
US8962643B2
(en)
|
2006-02-24 |
2015-02-24 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
WO2007143483A2
(en)
*
|
2006-06-01 |
2007-12-13 |
Smithkline Beecham Corporation |
Combination of pazopanib and lapatinib for treating cancer
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
CA2673125C
(en)
|
2006-10-19 |
2015-04-21 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2008079291A2
(en)
|
2006-12-20 |
2008-07-03 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
EP2118069B1
(en)
|
2007-01-09 |
2014-01-01 |
Amgen Inc. |
Bis-aryl amide derivatives useful for the treatment of cancer
|
FR2911604B1
(fr)
|
2007-01-19 |
2009-04-17 |
Sanofi Aventis Sa |
Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
|
US8314087B2
(en)
|
2007-02-16 |
2012-11-20 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and methods of use
|
TWI484960B
(zh)
*
|
2007-04-16 |
2015-05-21 |
Hutchison Medipharma Entpr Ltd |
嘧啶衍生物
|
JP5718640B2
(ja)
|
2007-08-21 |
2015-05-13 |
アムジエン・インコーポレーテツド |
ヒトc−fms抗原結合性タンパク質
|
EP2058307A1
(en)
|
2007-11-12 |
2009-05-13 |
Cellzome Ag |
Methods for the identification of JAK kinase interacting molecules and for the purification of JAK kinases
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
PT2323993E
(pt)
|
2008-04-16 |
2015-10-12 |
Portola Pharm Inc |
2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
|
WO2009136995A2
(en)
|
2008-04-16 |
2009-11-12 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk protein kinase
|
CN103224497A
(zh)
|
2008-04-22 |
2013-07-31 |
波托拉医药品公司 |
蛋白激酶抑制剂
|
HUE035029T2
(en)
|
2008-05-21 |
2018-03-28 |
Ariad Pharma Inc |
Kinase inhibitor phosphorus derivatives
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
US20100029689A1
(en)
*
|
2008-07-02 |
2010-02-04 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
WO2010036796A1
(en)
*
|
2008-09-26 |
2010-04-01 |
Concert Pharmaceuticals, Inc. |
Pyridineamine derivatives
|
FR2942227B1
(fr)
|
2009-02-13 |
2011-04-15 |
Guerbet Sa |
Utilisation de tampons pour la complexation de radionucleides
|
WO2011039648A1
(en)
|
2009-09-30 |
2011-04-07 |
Glaxo Wellcome Manufacturing Pte Ltd. |
Methods of administration and treatment
|
US20120197019A1
(en)
*
|
2009-10-23 |
2012-08-02 |
Dharmesh Surendra Bhanushali |
Compositions and processes
|
WO2011058179A1
(en)
|
2009-11-16 |
2011-05-19 |
Ratiopharm Gmbh |
5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
|
WO2011069053A1
(en)
|
2009-12-04 |
2011-06-09 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
|
UY33164A
(es)
*
|
2010-01-06 |
2011-08-31 |
Glaxo Wellcome Mfg Pte Ltd |
Metodo de tratamiento
|
WO2013022801A1
(en)
|
2011-08-05 |
2013-02-14 |
Forsight Vision4, Inc. |
Small molecule delivery with implantable therapeutic device
|
CA2794153C
(en)
|
2010-03-25 |
2018-01-02 |
Glaxosmithkline Llc |
Substituted indoline derivatives as perk inhibitors
|
JP5607241B2
(ja)
|
2010-05-21 |
2014-10-15 |
ケミリア・エービー |
新規ピリミジン誘導体
|
EP2575460A4
(en)
*
|
2010-05-26 |
2013-10-16 |
Glaxosmithkline Llc |
COMBINATION
|
MA34299B1
(fr)
|
2010-06-04 |
2013-06-01 |
Hoffmann La Roche |
Dérivés d'aminopyrimidine au titre de modulateurs de lrrk2
|
WO2011161217A2
(en)
|
2010-06-23 |
2011-12-29 |
Palacký University in Olomouc |
Targeting of vegfr2
|
EP2608790A4
(en)
|
2010-08-26 |
2014-04-02 |
Glaxosmithkline Llc |
PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
|
EP2616057A4
(en)
*
|
2010-09-14 |
2014-03-12 |
Glaxosmithkline Ip No 2 Ltd |
COMBINATION OF B-RAF AND VEGFR INHIBITORS
|
WO2012051587A1
(en)
*
|
2010-10-14 |
2012-04-19 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in egfr-driven cancers
|
US8846928B2
(en)
|
2010-11-01 |
2014-09-30 |
Portola Pharmaceuticals, Inc. |
Benzamides and nicotinamides as Syk modulators
|
US20130317029A1
(en)
|
2010-11-01 |
2013-11-28 |
Portola Pharmaceuticals, Inc. |
Oxypyrimidines as syk modulators
|
US9102625B2
(en)
|
2010-11-01 |
2015-08-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as JAK kinase modulators
|
AU2011328139A1
(en)
|
2010-11-10 |
2013-04-04 |
F. Hoffmann-La Roche Ag |
Pyrazole aminopyrimidine derivatives as LRRK2 modulators
|
CA2818612C
(en)
|
2010-11-19 |
2020-12-29 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
EP2646431B1
(en)
|
2010-11-29 |
2016-04-06 |
Hetero Research Foundation |
A process for the preparation of pazopanib using novel intermediate
|
CN102060848B
(zh)
*
|
2010-12-09 |
2013-09-18 |
天津药物研究院 |
芳香胺取代的嘧啶衍生物的制备及用途
|
CN102093339B
(zh)
*
|
2010-12-09 |
2013-06-12 |
天津药物研究院 |
一类嘧啶衍生物的制备及用途
|
CN102093340B
(zh)
*
|
2010-12-09 |
2013-07-17 |
天津药物研究院 |
2-甲基吲唑衍生物的制备及用途
|
EP2654754B1
(en)
|
2010-12-17 |
2016-12-21 |
Novartis AG |
Combination for treating osteosarcoma, rhabdomyosarcoma and neuroblastoma
|
FR2968999B1
(fr)
|
2010-12-20 |
2013-01-04 |
Guerbet Sa |
Nanoemulsion de chelate pour irm
|
JP2014504638A
(ja)
|
2011-02-01 |
2014-02-24 |
グラクソスミスクライン インテレクチュアル プロパティ リミテッド |
組合せ
|
WO2012129344A1
(en)
|
2011-03-23 |
2012-09-27 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
WO2012127032A1
(en)
|
2011-03-24 |
2012-09-27 |
Chemilia Ab |
Novel pyrimidine derivatives
|
JP5912172B2
(ja)
*
|
2011-04-19 |
2016-04-27 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH |
置換された4−アリール−n−フェニル−1,3,5−トリアジン−2−アミン
|
EA201391626A1
(ru)
|
2011-05-04 |
2014-03-31 |
Ариад Фармасьютикалз, Инк. |
Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
|
TWI555737B
(zh)
|
2011-05-24 |
2016-11-01 |
拜耳知識產權公司 |
含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
|
WO2013025939A2
(en)
|
2011-08-16 |
2013-02-21 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
EP2755948B1
(en)
*
|
2011-09-16 |
2016-05-25 |
Bayer Intellectual Property GmbH |
Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
|
FR2980364B1
(fr)
|
2011-09-26 |
2018-08-31 |
Guerbet |
Nanoemulsions et leur utilisation comme agents de contraste
|
KR101993436B1
(ko)
*
|
2011-10-31 |
2019-06-26 |
노바르티스 아게 |
파조파닙 제형
|
AU2012340555B2
(en)
|
2011-11-23 |
2016-10-20 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
CN103159742B
(zh)
*
|
2011-12-16 |
2015-08-12 |
北京韩美药品有限公司 |
5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
CN103373989B
(zh)
*
|
2012-04-28 |
2016-04-13 |
上海医药工业研究院 |
盐酸帕唑帕尼的中间体的制备方法
|
US20150166591A1
(en)
|
2012-05-05 |
2015-06-18 |
Ariad Pharmaceuticals, Inc. |
Methods and compositions for raf kinase mediated diseases
|
EP2890696A1
(en)
|
2012-08-29 |
2015-07-08 |
Amgen, Inc. |
Quinazolinone compounds and derivatives thereof
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
CA2888371C
(en)
|
2012-10-18 |
2021-06-08 |
Ulrich Lucking |
5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
|
WO2014060493A2
(en)
|
2012-10-18 |
2014-04-24 |
Bayer Pharma Aktiengesellschaft |
N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
|
TW201418243A
(zh)
|
2012-11-15 |
2014-05-16 |
Bayer Pharma AG |
含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
|
KR102242871B1
(ko)
|
2012-11-15 |
2021-04-20 |
바이엘 파마 악티엔게젤샤프트 |
술폭시민 기를 함유하는 5-플루오로-n-(피리딘-2-일)피리딘-2-아민 유도체
|
CN103864764A
(zh)
*
|
2012-12-11 |
2014-06-18 |
齐鲁制药有限公司 |
吲唑取代的嘧啶胺衍生物、其制备方法和用途
|
WO2014097152A1
(en)
|
2012-12-17 |
2014-06-26 |
Ranbaxy Laboratories Limited |
Process for the preparation of pazopanib or salts thereof
|
US9802923B2
(en)
*
|
2012-12-17 |
2017-10-31 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of pazopanib or salts thereof
|
CN103910716A
(zh)
*
|
2013-01-07 |
2014-07-09 |
华东理工大学 |
2,4-二取代-环烷基[d]嘧啶类化合物及其用途
|
CA2897559A1
(en)
|
2013-01-09 |
2014-07-17 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination
|
FR3001154B1
(fr)
|
2013-01-23 |
2015-06-26 |
Guerbet Sa |
Magneto-emulsion vectorisee
|
US9968603B2
(en)
|
2013-03-14 |
2018-05-15 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
CN103214467B
(zh)
*
|
2013-04-26 |
2015-09-30 |
中国人民解放军军事医学科学院微生物流行病研究所 |
5-[[4-[(2,3-二甲基-2h-吲唑-6-基)甲氨基]-2嘧啶基]氨基]-2-甲基-苯磺酰胺衍生物及其制备方法与应用
|
CN105492438B
(zh)
|
2013-07-04 |
2018-08-07 |
拜耳医药股份有限公司 |
磺亚胺取代的5-氟-n-(吡啶-2-基)吡啶-2-胺衍生物以及其作为cdk9激酶抑制剂的用途
|
ES2813877T3
(es)
|
2013-08-28 |
2021-03-25 |
Crown Bioscience Inc Taicang |
Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos
|
WO2015056180A1
(en)
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Indoline derivatives as inhibitors of perk
|
WO2015068175A2
(en)
|
2013-11-05 |
2015-05-14 |
Laurus Labs Private Limited |
An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
|
CN103739550B
(zh)
*
|
2014-01-02 |
2016-06-01 |
中国药科大学 |
2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
|
CN104829542B
(zh)
*
|
2014-02-10 |
2018-02-02 |
中国科学院上海药物研究所 |
苯胺嘧啶类化合物、其制备方法和医药用途
|
WO2015136463A1
(en)
|
2014-03-11 |
2015-09-17 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Chemical compounds acting as perk inhibitors
|
CA2942119A1
(en)
|
2014-03-13 |
2015-09-17 |
Bayer Pharma Aktiengesellschaft |
5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
|
EP3126338B1
(en)
|
2014-04-01 |
2019-09-04 |
Bayer Pharma Aktiengesellschaft |
Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
|
CU24399B1
(es)
|
2014-04-11 |
2019-04-04 |
Bayer Pharma AG |
Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos
|
WO2015166370A1
(en)
|
2014-04-28 |
2015-11-05 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
MY182793A
(en)
|
2014-08-08 |
2021-02-05 |
Forsight Vision4 Inc |
Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
|
WO2016055935A1
(en)
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
CA2964683A1
(en)
|
2014-10-16 |
2016-04-21 |
Bayer Pharma Aktiengesellschaft |
Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
|
EP3207038B1
(en)
|
2014-10-16 |
2018-08-22 |
Bayer Pharma Aktiengesellschaft |
Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
|
WO2016112111A1
(en)
|
2015-01-08 |
2016-07-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Factors and cells that provide for induction of bone, bone marrow, and cartilage
|
EP3789027A1
(en)
|
2015-01-13 |
2021-03-10 |
Kyoto University |
Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
|
KR101705980B1
(ko)
*
|
2015-06-12 |
2017-02-13 |
중앙대학교 산학협력단 |
신규 파조파닙 유도체 및 이를 함유하는 약학조성물
|
CN105237523B
(zh)
*
|
2015-10-08 |
2018-06-01 |
深圳市博圣康生物科技有限公司 |
嘧啶衍生物及其制备方法、用途
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
EP3228630A1
(en)
|
2016-04-07 |
2017-10-11 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
|
KR20190015492A
(ko)
|
2016-06-08 |
2019-02-13 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
화학적 화합물
|
KR20190015748A
(ko)
|
2016-06-08 |
2019-02-14 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
Atf4 경로 억제제로서의 화학적 화합물
|
EP3487503A1
(en)
|
2016-07-20 |
2019-05-29 |
GlaxoSmithKline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
JP2020510618A
(ja)
|
2016-12-01 |
2020-04-09 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
癌を処置する方法
|
HUE056777T2
(hu)
|
2016-12-22 |
2022-03-28 |
Amgen Inc |
Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére
|
US11426406B2
(en)
|
2017-02-09 |
2022-08-30 |
Georgetown University |
Compositions and methods for treating lysosomal storage disorders
|
ES2900199T3
(es)
|
2017-03-28 |
2022-03-16 |
Bayer Ag |
Novedosos compuestos macrocíclicos inhibidores de PTEFB
|
US11242356B2
(en)
|
2017-03-28 |
2022-02-08 |
Bayer Aktiengesellschaft |
PTEFb inhibiting macrocyclic compounds
|
IL270070B2
(en)
|
2017-04-17 |
2023-09-01 |
Univ Yale |
Compounds, compositions and methods for treating or preventing acute lung injury
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
JP2020525513A
(ja)
|
2017-07-03 |
2020-08-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
癌および他の疾患を治療するためのatf4阻害剤としてのn−(3−(2−(4−クロロフェノキシ)アセトアミドビシクロ[1.1.1]ペンタン−1−イル)−2−シクロブタン−1−カルボキサミド誘導体および関連化合物
|
US20200140383A1
(en)
|
2017-07-03 |
2020-05-07 |
Glaxosmithkline Intellectual Property Development Limited |
2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
CN107619407B
(zh)
*
|
2017-08-10 |
2019-05-24 |
山东大学 |
基于帕唑帕尼结构的hdac和vegfr双靶点抑制剂及其制备方法和应用
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
JP7150823B2
(ja)
|
2017-09-08 |
2022-10-11 |
アムジエン・インコーポレーテツド |
KRas G12Cの阻害剤及びそれを使用する方法
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
EA202091894A1
(ru)
|
2018-02-13 |
2020-12-28 |
Байер Акциенгезельшафт |
Применение 5-фтор-4-(4-фтор-2-метоксифенил)-n-{4-[(s-метилсульфонимидоил)метил]пиридин-2-ил}пиридин-2-амина для лечения диффузной в-крупноклеточной лимфомы
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
WO2019053500A1
(en)
|
2018-04-17 |
2019-03-21 |
Alvogen Malta Operations (Row) Ltd |
PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE FORM CONTAINING PAZOPANIB AND PROCESS FOR PREPARING THE SAME
|
JP7361722B2
(ja)
|
2018-05-04 |
2023-10-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤及び同一物の使用方法
|
US11090304B2
(en)
|
2018-05-04 |
2021-08-17 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
EP3790886A1
(en)
|
2018-05-10 |
2021-03-17 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
WO2019232419A1
(en)
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CA3099799A1
(en)
|
2018-06-11 |
2019-12-19 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
AU2019336588B2
(en)
|
2018-06-12 |
2022-07-28 |
Amgen Inc. |
KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
TWI815137B
(zh)
|
2018-06-15 |
2023-09-11 |
漢達生技醫藥股份有限公司 |
尼洛替尼十二烷基硫酸鹽之結晶
|
WO2020007822A1
(en)
|
2018-07-02 |
2020-01-09 |
Conservatoire National Des Arts Et Metiers (Cnam) |
Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
|
WO2020012339A1
(en)
|
2018-07-09 |
2020-01-16 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
CA3117222A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
BR112021010353A2
(pt)
|
2018-11-30 |
2021-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Compostos úteis em terapia hiv
|
EP3897855B1
(en)
|
2018-12-20 |
2023-06-07 |
Amgen Inc. |
Kif18a inhibitors
|
WO2020132653A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
EP3897852A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Kif18a inhibitors
|
EP3898616A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
MX2021010319A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos biciclicos de heteroarilo y usos de estos.
|
CA3130083A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
SG11202112855WA
(en)
|
2019-05-21 |
2021-12-30 |
Amgen Inc |
Solid state forms
|
WO2021018941A1
(en)
|
2019-07-31 |
2021-02-04 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
WO2021026101A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
AU2020325115A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
Pyridine derivatives as KIF18A inhibitors
|
CA3147272A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN110746402B
(zh)
*
|
2019-09-21 |
2021-01-15 |
温州医科大学 |
一种2-n-芳基-4-n-芳基-5-氟嘧啶类化合物及其制备方法和应用
|
CA3155857A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
|
MX2022005359A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
AU2020379731A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
EP4055028A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN114901662A
(zh)
|
2019-11-08 |
2022-08-12 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
US20230192682A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
AU2020381492A1
(en)
|
2019-11-14 |
2022-05-26 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
JP2023509701A
(ja)
|
2020-01-07 |
2023-03-09 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Shp2阻害剤投薬およびがんを処置する方法
|
US20230181582A1
(en)
|
2020-05-22 |
2023-06-15 |
Qx Therapeutics Inc. |
Compositions and methods for treating lung injuries associated with viral infections
|
AU2021293228A1
(en)
|
2020-06-18 |
2023-02-09 |
Revolution Medicines, Inc. |
Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors
|
WO2022040446A1
(en)
|
2020-08-19 |
2022-02-24 |
Nanocopoeia, Llc |
Amorphous pazopanib particles and pharmaceutical compositions thereof
|
AU2021344830A1
(en)
|
2020-09-03 |
2023-04-06 |
Revolution Medicines, Inc. |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
KR20230067635A
(ko)
|
2020-09-15 |
2023-05-16 |
레볼루션 메디슨즈, 인크. |
암의 치료에서 ras 억제제로서 인돌 유도체
|
JP2024501280A
(ja)
|
2020-12-22 |
2024-01-11 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Sos1阻害剤およびその使用
|
WO2022235870A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
WO2022235864A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2023230541A1
(en)
|
2022-05-27 |
2023-11-30 |
Viiv Healthcare Company |
Piperazine derivatives useful in hiv therapy
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|